Last reviewed · How we verify
F#13418-158 Eye Drops
F#13418-158 is an ophthalmic formulation designed to treat dry eye disease by lubricating and protecting the ocular surface.
F#13418-158 is an ophthalmic formulation designed to treat dry eye disease by lubricating and protecting the ocular surface. Used for Dry eye disease (presumed, based on formulation type).
At a glance
| Generic name | F#13418-158 Eye Drops |
|---|---|
| Sponsor | Johnson & Johnson Consumer Inc. (J&JCI) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
As an eye drop formulation in Phase 3 development by Johnson & Johnson Consumer Inc., this drug likely works through ocular surface lubrication and/or anti-inflammatory mechanisms to alleviate symptoms of dry eye disease. The specific active pharmaceutical ingredient and exact mechanism are not publicly disclosed in available sources, but the therapeutic class suggests symptom relief and corneal protection.
Approved indications
- Dry eye disease (presumed, based on formulation type)
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- F#13418-158 Eye Drops CI brief — competitive landscape report
- F#13418-158 Eye Drops updates RSS · CI watch RSS
- Johnson & Johnson Consumer Inc. (J&JCI) portfolio CI